Our coverage of ACC 2025 in Chicago dominated our most-read stories, but other news on novel therapies made the list, too.

The choice between ICD types still should be based on each individual patient’s risk factors, Kenneth Ellenbogen says.

The novel aldosterone inhibitor works, but longer-term safety data are needed before the drug might be approved.